Organization | Shionogi

Shionogi Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Osaka Japan (1878)

Organization Overview

First Clinical Trial

2001

NCT00033215

First Marketed Drug

1967

mefenamic acid (ponstel)

First NDA Approval

1993

tacrine (cognex)

Last Known Activity

2022

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Shionogi | Shionogi Inc. | SHIONOGI INC

Active Ingredients

Marketed Drugs (10)

Key: Shionogi (9) Acquired (1)

baloxavir marboxil (xofluza) (2018 NDA)

benzyl alcohol (ulesfia) (2009)

cefiderocol (Fetroja) (2019 NDA)

doripenem (doribax) (2007)

Lusutrombopag (Mulpleta) (2018 NDA)

mefenamic acid (ponstel) (1967)

naldemedine (symproic) (2017 NDA)

ospemifene (osphena) (2013 NDA)

tacrine (cognex) (1993 NDA)

tramadol (Ultram) (2005)

Drugs in Phase 4 Trials (5)

Key: Shionogi (4) Acquired (1)

cefiderocol (Fetroja) (12 trials)

clonidine (catapres) (4 trials)

duloxetine (Cymbalta) (11 trials)

pregabalin (lyrica) (1 trial)

rosuvastatin (crestor) (1 trial)

Drugs in Phase 3 Trials (22)

Key: Shionogi (18) Acquired (4)

abacavir (ziagen) (4 trials)

baloxavir marboxil (xofluza) (3 trials)

bpn14770 (8 trials)

dolutegravir (tivicay) (31 trials)

efavirenz (sustiva) (3 trials)

emtricitabine (emtriva) (2 trials)

fenofibrate (fenoglide) (2 trials)

glycopyrronium (robinul) (1 trial)

inactivated influenza vaccine (6 trials)

lamivudine (epivir) (4 trials)

lidocaine (xylocaine) (3 trials)

linezolid (zyvox) (1 trial)

Lusutrombopag (Mulpleta) (4 trials)

meropenem (merrem) (1 trial)

naldemedine (symproic) (7 trials)

oseltamivir (tamiflu) (2 trials)

ospemifene (osphena) (7 trials)

pravastatin (pravachol) (1 trial)

prilocaine (citanest) (3 trials)

raltegravir (isentress) (2 trials)

tenofovir (viread) (2 trials)

tivantinib (2 trials)

Drugs in Phase 2 Trials (27)

Key: Shionogi (22) Acquired (5)

adx415 (1 trial)

asapiprant (1 trial)

asp7373 (1 trial)

becocalcidiol (1 trial)

cabotegravir (Vocabria) (3 trials)

cetirizine (zyrtec) (1 trial)

cilastatin (primaxin) (1 trial)

durvalumab (imfinzi) (1 trial)

fispemifene (3 trials)

gw810781 (1 trial)

imipenem (primaxin) (1 trial)

influenza vaccine, recombinant hemagglutinin (1 trial)

montanide isa51 (1 trial)

naproxen (naprosyn) (1 trial)

orlistat (xenical) (1 trial)

pembrolizumab (keytruda) (1 trial)

velneperit (4 trials)

Drugs in Phase 1 Trials (33)

Key: Shionogi (31) Acquired (2)

aluminum hydroxide (Gaviscon) (1 trial)

atazanavir (reyataz) (1 trial)

boceprevir (victrelis) (1 trial)

calcium carbonate (1 trial)

darunavir (prezista) (1 trial)

donepezil (aricept) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

etravirine (intelence) (1 trial)

fosamprenavir (lexiva) (1 trial)

iohexol (Omnipaque) (1 trial)

lopinavir (Kaletra) (1 trial)

magnesium hydroxide (1 trial)

methadone (methadose) (1 trial)

midazolam (versed) (2 trials)

moxifloxacin (avelox) (1 trial)

norgestimate (1 trial)

omeprazole (prilosec) (1 trial)

p-aminohippuric acid (1 trial)

pirfenidone (esbriet) (1 trial)

prednisone (meticorten) (1 trial)

rifabutin (mycobutin) (1 trial)

rifampin (1 trial)

rilpivirine (edurant) (1 trial)

ritonavir (Norvir) (3 trials)

s-217622 (2 trials)

s-648414 (1 trial)

scopolamine (transderm scop) (1 trial)

secukinumab (cosentyx) (2 trials)

simethicone (IMODIUM) (1 trial)

sitagliptin (januvia) (1 trial)

tbi-1201 (1 trial)

tbi-1301 (1 trial)

telaprevir (incivek) (1 trial)

Drugs in Other Trials (1)

cetrorelix (cetrotide) (1 trial)

Indications

Approved Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 3)

Atrophy (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Back Pain (Phase 3)

Bacterial Infections (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cerebral Palsy (Phase 3)

Chronic Pain (Phase 2)

Communicable Diseases (Phase 3)

Constipation (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Cough (Phase 2)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Neuropathies (Phase 4)

Disease (Phase 3)

Eczema (Phase 2)

Fibromyalgia (Phase 3)

Fibrosis (Phase 2)

Gastrointestinal Diseases (Phase 2)

Gram-Negative Bacterial Infections (Phase 2)

Healthcare-Associated Pneumonia (Phase 3)

Heart Diseases (Phase 4)

HIV Infections (Phase 3)

Hypercholesterolemia (Phase 4)

Hyperkinesis (Phase 4)

Hyperlipidemia, Familial Combined (Phase 3)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Infections (Phase 3)

Influenza, Human (Phase 3)

Intellectual Disability (Phase 3)

Intestinal Diseases (Phase 2)

Intraabdominal Infections (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Cirrhosis, Biliary (Phase 2)

Liver Diseases (Phase 3)

Low Back Pain (Phase 3)

Lung Neoplasms (Phase 2)

Mesothelioma (Phase 1)

Myocardial Ischemia (Phase 4)

Myofascial Pain Syndromes (Phase 3)

Neoplasms (Phase 1)

Neuralgia (Phase 4)

Obesity (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Paralysis (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 1)

Pneumonia, Ventilator-Associated (Phase 3)

Premature Birth (Phase 3)

Premature Ejaculation (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Pyelonephritis (Phase 2)

Respiratory Aspiration (Phase 1)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Sialorrhea (Phase 3)

Thrombocytopenia (Phase 3)

Tuberculosis (Phase 1)

Urinary Bladder Neoplasms (Phase 2)

Urinary Tract Infections (Phase 3)

Vaginal Diseases (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 135
# of Trial APIs: 88